Importantly, pan PPAR agonist has shown effective outcomes in clinical trials on type 2 diabetes, NAFLD, and cutaneous systemic sclerosis [45–46], which prompted us to evaluate the potency of pan PPAR agonist as a priming factor for EV production. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.